Novel pretreatment nomograms based on pan-immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma.

Front Oncol · 2024 · PMC11194608 · PMID 38915366

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

did not reach statistical significancep =0.069so close (0.05 < p ≤ 0.1)

Despite that similar trends were observed in stage II and IV patients, the results did not reach statistical significance (stage II: 71.4% vs. 29.4%, HR: 3.59, 95% CI: 1.22–10.60, p =0.069; stage IV: 16.7% vs. 14.8%, HR: 1.86, 95% CI: 0.94–3.69, p =0.083, Supplementary Figures 5B, D ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.